# Risk Management Plan (RMP) Survey for Purchasers of Alli® (60 mg Orlistat) in the European Union.

> **NCT02141230** · NA · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Weight Loss

## Interventions

- **DRUG:** Alli® 60 mg

## Key facts

- **NCT ID:** NCT02141230
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-12
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-06-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02141230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02141230, "Risk Management Plan (RMP) Survey for Purchasers of Alli® (60 mg Orlistat) in the European Union.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02141230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*